Cryo-Cell International, Inc.
Explore Cryo-Cell International, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
CCEL — Monthly Price History
Adjusted close price · Hover to see price & month
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Meaningful dividend yield is available.
Cons
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tenet Healthcare Corporation | $162.06 | 8.23 | $14.01 B | — | 13.64% | 40.55% | $247.21 / $146.6 | $48.53 |
| 2. | DaVita Inc. | $192.16 | 15.81 | $12.36 B | — | 14.02% | 181.22% | $202.69 / $101 | $1.5 |
| 3. | Encompass Health Corporation | $104.01 | 16.94 | $10.32 B | 0.76% | 16.84% | 25.35% | $127.99 / $92.77 | $24.38 |
| 4. | The Ensign Group, Inc. | $170.3 | 26.94 | $9.79 B | 0.16% | 9.31% | 16.64% | $218 / $134.79 | $38.42 |
| 5. | Universal Health Services, Inc. | $145.17 | 5.68 | $8.64 B | 0.56% | 16.23% | 21.02% | $246.33 / $140.76 | $119.15 |
| 6. | PACS Group, Inc. | $37.01 | 24.33 | $5.93 B | — | 6.76% | 26.63% | $43.08 / $7.5 | $6.05 |
| 7. | Chemed Corporation | $441.59 | 22.45 | $5.83 B | 0.56% | 27.27% | 25.33% | $565.66 / $365.21 | $71.43 |
Quarterly Results
Figures shown in M / B
| Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 7.68 M | 7.84 M | 7.93 M | 7.97 M | 8.02 M | — |
| Operating Profit | 0.77 M | 0.39 M | 1.49 M | 1.06 M | -0.12 M | — |
| Net Profit | 0.05 M | -3.82 M | 0.36 M | 0.28 M | -1.86 M | — |
| EPS in Rs | 0.01 | -0.47 | 0.04 | 0.04 | -0.23 | 0.13 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 31.57 M | 31.99 M | 31.34 M | 30.34 M |
| Operating Profit | 4.84 M | 3.79 M | 3.49 M | 4.46 M |
| Net Profit | -2.43 M | 0.4 M | -9.52 M | 2.77 M |
| EPS in Rs | -0.3 | 0.05 | -1.18 | 0.34 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 61.73 M | 64.68 M | 61.22 M | 64.89 M |
| Total Liabilities | 80.33 M | 77.89 M | 72.25 M | 66.41 M |
| Equity | -18.61 M | -13.22 M | -11.03 M | -1.52 M |
| Current Assets | 11.76 M | 12.55 M | 9.45 M | 9.61 M |
| Current Liabilities | 19.79 M | 21.6 M | 20.86 M | 19.48 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 5.48 M | 6.01 M | 8.92 M | 8.57 M |
| Investing CF | -0.98 M | -4.88 M | -8.14 M | -15.28 M |
| Financing CF | -4.75 M | -0.98 M | -2.07 M | 0.15 M |
| Free CF | 5.25 M | 2.41 M | 1.28 M | -8.6 M |
| Capex | -0.23 M | -3.6 M | -7.64 M | -17.17 M |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 2.05% | 3.32% | — | — |
| Earnings Growth % | 104.22% | -443.57% | — | — |
| Profit Margin % | 1.26% | -30.38% | 9.14% | — |
| Operating Margin % | 11.84% | 11.14% | 14.7% | — |
| Gross Margin % | 75.15% | 73.23% | 71.02% | — |
| EBITDA Margin % | 17.79% | -33.24% | 21.92% | — |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
| Ex Date | Dividend |
|---|---|
| 2025-05-21 | $0.15 |
| 2025-02-14 | $0.25 |
| 2024-11-15 | $0.25 |
| 2022-09-01 | $0.9 |
Stock Splits
No stock split history available.
Frequently Asked Questions — Cryo-Cell International, Inc.
Will Cryo-Cell International, Inc. stock hit $4 in 2026?
Cryo-Cell International, Inc. (CCEL) is currently trading at $3.50, with a 52-week range of $2.72 to $6.35. Reaching the $4 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.
Whether Cryo-Cell International, Inc. can reach $4 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.
Historically, CCEL has delivered a -12.5% CAGR over the past 5 years, which suggests the stock has demonstrated meaningful long-term growth momentum. However, past performance does not guarantee future results, and short-term price movements can be influenced by macroeconomic shifts, interest rate changes, and investor sentiment. Use the CCEL Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.
Is Cryo-Cell International, Inc. stock worth buying at $3.50?
Whether Cryo-Cell International, Inc. (CCEL) is worth buying at $3.50 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:
Valuation: Valuation data is currently limited — check the full ratios section on StockSifting for the latest P/E, P/B, and EV/EBITDA figures.
Profitability & efficiency: Cryo-Cell International, Inc. has a Return on Capital Employed (ROCE) of 11.5%, which reflects modest capital efficiency. Its Return on Equity (ROE) stands at 38.2%, suggesting management is effectively converting shareholder equity into profit.
Financial health: The Debt-to-Equity ratio of -0.62 indicates a conservative balance sheet with more equity than debt, reducing financial risk.
Analyst view: Analyst estimates are not currently available for CCEL. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.
What is the analyst price target for Cryo-Cell International, Inc. (CCEL) in 2026?
Analyst price target data for Cryo-Cell International, Inc. (CCEL) is not currently available on StockSifting. Analyst coverage and price targets are typically published by brokerage research desks for widely followed stocks, and are updated regularly after earnings results or major corporate events. Check back for the latest estimates, or explore CCEL's financial ratios, historical returns, and fundamental data available on this page to form your own view.
How much can you earn by reinvesting Cryo-Cell International, Inc. dividends?
Dividend reinvestment — commonly known as DRIP (Dividend Reinvestment Plan) — is a powerful wealth-building strategy where instead of receiving your dividend payouts as cash, the dividends are automatically used to purchase additional shares of Cryo-Cell International, Inc. (CCEL). Over time, this creates a compounding effect: more shares generate more dividends, which buy even more shares.
Cryo-Cell International, Inc. currently offers a dividend yield of approximately 1143.00%. While this may seem modest in isolation, the real power of DRIP emerges over long holding periods. An investor who reinvested dividends consistently over 10–20 years would accumulate significantly more shares than one who took dividends as cash — and those extra shares continue generating their own dividend income.
The key variables that determine your DRIP returns are: your initial investment amount, the number of years you stay invested, the dividend yield at the time of each reinvestment, and whether Cryo-Cell International, Inc. grows or cuts its dividend over time. Market price appreciation of CCEL also plays a significant role — rising share prices increase the value of your accumulated shares.
Use the CCEL DRIP Calculator on StockSifting to enter your investment amount, start date, and contribution frequency — and see a year-by-year breakdown of shares accumulated, dividends earned, and total portfolio value. Past dividend payments are not a guarantee of future payouts. This is not financial advice.